NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

I have no doubt it happened. You can see around the same time LP signed two collaboration deal with two main players on checking point inhibitors. Colorectal trial with Merck and rGBM, a much tougher target with BMS. Merck cannot terminate the colorectal trial and then later became one of the collaborators of the combo trial with the termination of the collaboration trial between BMS and NWBO.

I suspect the reason they chose trial site at EU is that before January 2023, clinical trial was not required to be registered on public website.